Innovent Biologics (suzhou) Co. Ltd.

This study tests a new drug called IBI343 combined with other treatments for people with advanced stomach or pancreatic cancers that have a specific marker (CLDN18.2). The goal is to see if the combination is safe and can shrink tumors. About 389 adults with these cancers will ta…

This study tests a drug called IBI363 given before surgery for people with stage II or III non-small cell lung cancer that can be removed. The goal is to see if the drug can eliminate or shrink the tumor before the operation. Ten participants will receive IBI363, and doctors will…

This study tests a combination of three treatments (IBI343, sintilimab, and chemotherapy) given before and after surgery for advanced stomach or gastroesophageal junction cancer. About 90 adults whose tumors have a specific marker (CLDN18.2) will participate. The goal is to see i…

This early-stage study tests the safety and how the body handles a single dose of IBI3033 in 32 healthy Chinese adults aged 18-55. Participants receive either the drug or a placebo and are monitored for side effects and drug levels over 12 weeks. The goal is to gather essential s…